Skip to content
Conditions & Health

MASH

Metabolic dysfunction-associated steatohepatitis (formerly NASH). Inflammatory liver disease with fat accumulation, hepatocyte damage, and fibrosis risk. Survodutide and semaglutide are in trials for MASH treatment.

Frequently Asked Questions

What is MASH?
Metabolic dysfunction-associated steatohepatitis (formerly NASH). Inflammatory liver disease with fat accumulation, hepatocyte damage, and fibrosis risk. Survodutide and semaglutide are in trials for MASH treatment.
Why is MASH important in peptide research?
Understanding mash is important because it represents a health condition where peptide interventions are being actively researched. Knowledge of the underlying pathology helps inform peptide selection and protocol design.

Related Terms

NAFLD (non-alcoholic fatty liver disease)

Accumulation of fat in the liver not caused by alcohol consumption, affecting up to 30% of adults. Can progress to MASH (inflammatory liver damage). GLP-1 agonists and survodutide show promise in reducing liver fat.

Fibrosis

The excessive formation of fibrous connective tissue in an organ, impairing its function. Can affect the liver (cirrhosis), lungs (pulmonary fibrosis), or any injured tissue. Anti-fibrotic peptide research is active.

Inflammation

The body’s immune response to injury, infection, or irritation. Acute inflammation is protective; chronic inflammation drives disease. Many peptides (BPC-157, KPV, LL-37, Thymosin Alpha-1) modulate inflammatory pathways.

Related Peptide Profiles

Survodutide

An investigational dual glucagon/GLP-1 receptor agonist in development for obesity and metabolic liver disease (MASH).

Semaglutide

A GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and weight management (Wegovy). Reduces appetite and slows gastric emptying.

← Back to full glossary